Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer

Tibor Szarvas, Tobias Jäger, Markus Becker, Stephan Tschirdewahn, Christian Niedworok, I. Kovalszky, Herbert Rübben, Süleyman Ergün, Frank Vom Dorp

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Molecular marker analyses aiming a more accurate disease characterization and risk stratification of cancer patients provided several promising marker candidates in the last few years. However, recent reviews underlined the paramount importance of validation, since many of the initially promising results could not be confirmed in independent patient cohorts. If serum or plasma is a more appropriate sample to test for prognostic markers is a matter of debate. We recently found serum MMP-7 levels to correlate with poor patients' prognosis in urinary bladder cancer. In this study, we examined associations of the MMP-7 plasma levels with clinical follow-up data in an independent cohort of bladder cancer patients to validate our former results and to assess if plasma is also suitable for MMP-7 analysis. Plasma levels of 97 patients and 22 controls were analyzed, using enzyme-linked immunosorbent assay. Associations between MMP-7 plasma concentrations and clinical data were assessed applying both univariate and multivariate analysis. Plasma MMP-7 levels were significantly higher in patients than in controls. Similarly to our former findings in sera, high MMP-7 plasma levels proved to be significant and independent predictors of both overall and disease-specific survival. In addition, we observed a metastasis-specific difference in MMP-7 levels between serum and plasma. In summary, we confirmed the prognostic relevance of circulating MMP-7 levels in an independent cohort of patients and concluded that circulating MMP-7 levels may help to identify bladder cancer patients at high-risk of disease progression who could benefit from an adjuvant chemotherapy or from an extended lymph node dissection.

Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalPathology and Oncology Research
Volume17
Issue number2
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Matrix Metalloproteinases
Urinary Bladder Neoplasms
Survival
Serum
Adjuvant Chemotherapy
Lymph Node Excision
Disease Progression
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis

Keywords

  • Bladder cancer
  • Matrilysin
  • Metastasis
  • MMP-7
  • Plasma
  • Prognosis
  • Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. / Szarvas, Tibor; Jäger, Tobias; Becker, Markus; Tschirdewahn, Stephan; Niedworok, Christian; Kovalszky, I.; Rübben, Herbert; Ergün, Süleyman; Vom Dorp, Frank.

In: Pathology and Oncology Research, Vol. 17, No. 2, 06.2011, p. 325-332.

Research output: Contribution to journalArticle

Szarvas, T, Jäger, T, Becker, M, Tschirdewahn, S, Niedworok, C, Kovalszky, I, Rübben, H, Ergün, S & Vom Dorp, F 2011, 'Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer', Pathology and Oncology Research, vol. 17, no. 2, pp. 325-332. https://doi.org/10.1007/s12253-010-9320-4
Szarvas, Tibor ; Jäger, Tobias ; Becker, Markus ; Tschirdewahn, Stephan ; Niedworok, Christian ; Kovalszky, I. ; Rübben, Herbert ; Ergün, Süleyman ; Vom Dorp, Frank. / Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. In: Pathology and Oncology Research. 2011 ; Vol. 17, No. 2. pp. 325-332.
@article{aa506600162a4da2a3793e0c0dd90928,
title = "Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer",
abstract = "Molecular marker analyses aiming a more accurate disease characterization and risk stratification of cancer patients provided several promising marker candidates in the last few years. However, recent reviews underlined the paramount importance of validation, since many of the initially promising results could not be confirmed in independent patient cohorts. If serum or plasma is a more appropriate sample to test for prognostic markers is a matter of debate. We recently found serum MMP-7 levels to correlate with poor patients' prognosis in urinary bladder cancer. In this study, we examined associations of the MMP-7 plasma levels with clinical follow-up data in an independent cohort of bladder cancer patients to validate our former results and to assess if plasma is also suitable for MMP-7 analysis. Plasma levels of 97 patients and 22 controls were analyzed, using enzyme-linked immunosorbent assay. Associations between MMP-7 plasma concentrations and clinical data were assessed applying both univariate and multivariate analysis. Plasma MMP-7 levels were significantly higher in patients than in controls. Similarly to our former findings in sera, high MMP-7 plasma levels proved to be significant and independent predictors of both overall and disease-specific survival. In addition, we observed a metastasis-specific difference in MMP-7 levels between serum and plasma. In summary, we confirmed the prognostic relevance of circulating MMP-7 levels in an independent cohort of patients and concluded that circulating MMP-7 levels may help to identify bladder cancer patients at high-risk of disease progression who could benefit from an adjuvant chemotherapy or from an extended lymph node dissection.",
keywords = "Bladder cancer, Matrilysin, Metastasis, MMP-7, Plasma, Prognosis, Serum",
author = "Tibor Szarvas and Tobias J{\"a}ger and Markus Becker and Stephan Tschirdewahn and Christian Niedworok and I. Kovalszky and Herbert R{\"u}bben and S{\"u}leyman Erg{\"u}n and {Vom Dorp}, Frank",
year = "2011",
month = "6",
doi = "10.1007/s12253-010-9320-4",
language = "English",
volume = "17",
pages = "325--332",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer

AU - Szarvas, Tibor

AU - Jäger, Tobias

AU - Becker, Markus

AU - Tschirdewahn, Stephan

AU - Niedworok, Christian

AU - Kovalszky, I.

AU - Rübben, Herbert

AU - Ergün, Süleyman

AU - Vom Dorp, Frank

PY - 2011/6

Y1 - 2011/6

N2 - Molecular marker analyses aiming a more accurate disease characterization and risk stratification of cancer patients provided several promising marker candidates in the last few years. However, recent reviews underlined the paramount importance of validation, since many of the initially promising results could not be confirmed in independent patient cohorts. If serum or plasma is a more appropriate sample to test for prognostic markers is a matter of debate. We recently found serum MMP-7 levels to correlate with poor patients' prognosis in urinary bladder cancer. In this study, we examined associations of the MMP-7 plasma levels with clinical follow-up data in an independent cohort of bladder cancer patients to validate our former results and to assess if plasma is also suitable for MMP-7 analysis. Plasma levels of 97 patients and 22 controls were analyzed, using enzyme-linked immunosorbent assay. Associations between MMP-7 plasma concentrations and clinical data were assessed applying both univariate and multivariate analysis. Plasma MMP-7 levels were significantly higher in patients than in controls. Similarly to our former findings in sera, high MMP-7 plasma levels proved to be significant and independent predictors of both overall and disease-specific survival. In addition, we observed a metastasis-specific difference in MMP-7 levels between serum and plasma. In summary, we confirmed the prognostic relevance of circulating MMP-7 levels in an independent cohort of patients and concluded that circulating MMP-7 levels may help to identify bladder cancer patients at high-risk of disease progression who could benefit from an adjuvant chemotherapy or from an extended lymph node dissection.

AB - Molecular marker analyses aiming a more accurate disease characterization and risk stratification of cancer patients provided several promising marker candidates in the last few years. However, recent reviews underlined the paramount importance of validation, since many of the initially promising results could not be confirmed in independent patient cohorts. If serum or plasma is a more appropriate sample to test for prognostic markers is a matter of debate. We recently found serum MMP-7 levels to correlate with poor patients' prognosis in urinary bladder cancer. In this study, we examined associations of the MMP-7 plasma levels with clinical follow-up data in an independent cohort of bladder cancer patients to validate our former results and to assess if plasma is also suitable for MMP-7 analysis. Plasma levels of 97 patients and 22 controls were analyzed, using enzyme-linked immunosorbent assay. Associations between MMP-7 plasma concentrations and clinical data were assessed applying both univariate and multivariate analysis. Plasma MMP-7 levels were significantly higher in patients than in controls. Similarly to our former findings in sera, high MMP-7 plasma levels proved to be significant and independent predictors of both overall and disease-specific survival. In addition, we observed a metastasis-specific difference in MMP-7 levels between serum and plasma. In summary, we confirmed the prognostic relevance of circulating MMP-7 levels in an independent cohort of patients and concluded that circulating MMP-7 levels may help to identify bladder cancer patients at high-risk of disease progression who could benefit from an adjuvant chemotherapy or from an extended lymph node dissection.

KW - Bladder cancer

KW - Matrilysin

KW - Metastasis

KW - MMP-7

KW - Plasma

KW - Prognosis

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=80051668046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051668046&partnerID=8YFLogxK

U2 - 10.1007/s12253-010-9320-4

DO - 10.1007/s12253-010-9320-4

M3 - Article

C2 - 21253919

AN - SCOPUS:80051668046

VL - 17

SP - 325

EP - 332

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -